Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

lly different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. You are urged to consider statements that include the words "ongoing," "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "suggests," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... -- McGraw-Hill Education Professional, a leading global provider of ... communities, has announced the launch of the AccessMedicine ... world-renowned medical education platform. A key ... for download onto all iOS and Android devices, is ... to valuable AccessMedicine diagnostic resources in an ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Institute at Boca Raton Regional Hospital has established itself as ... his team have treated over 100 patients using Protura, and ... Using KV -- CBCT Imaging Guided 6D Robotic Couch in ... (Logo:   http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) Williams has a ...
... CITY, Calif., July 27, 2011 Genomic Health, Inc. (Nasdaq: ... conference call and webcast on Wednesday, August 3 at 4:30 p.m. ... call and webcast will follow the release of the second quarter ... Details To access the live conference call ...
Cached Medicine Technology:Boca Raton Regional Hospital Treats Over 100 Patients Annually with CIVCO's Protura™ 2Boca Raton Regional Hospital Treats Over 100 Patients Annually with CIVCO's Protura™ 3Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 2Genomic Health to Announce Second Quarter 2011 Financial Results and Host Conference Call on Wednesday, August 3, 2011 3
(Date:7/29/2014)... 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. , The study finds that ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is ... a non-profit organization providing grief camps for kids, teens, adults, ... suffering our clients experience from the death of a loved ... organization like Stepping Stones of Hope, as they provide hope ... of Hope also includes a monthly support group and a ...
(Date:7/29/2014)... record the severity and regularity of their pain is ... , A new approach to the treatment of headaches, ... and is being led by Professor Paul Martin from ... He has developed an approach designed to enable people ... Learning to Cope with Triggers (LCT). , Using a ...
(Date:7/29/2014)... cases of cancer is to surgically remove the tumor. ... the surgeon may fail to extract the entire tumor, ... technique, researchers at the University of Pennsylvania have established ... tumor in the patient, increasing the likelihood of a ... that accumulates in cancerous tissues much more so than ...
(Date:7/29/2014)... A new 3-part video series: The Cost/Benefit ... Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las ... review the benefits of ACE accreditation and the cost/benefit ... laboratory from the perspective of clinicians who have worked ... MS, RN, Director of Cardiac and Interventional Services at ...
Breaking Medicine News(10 mins):Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Launches 3-Part Video Series: The Cost/Benefit of ACE Accreditation; ProMedica Toledo Hospital Achieves Accreditation 3
... combo uncovered 80% of early-stage tumors, researchers say, , , MONDAY, ... level of early-stage ovarian cancer detection by 20 percent through ... as well as a woman,s report of new-onset symptoms. ... of early-stage ovarian cancers in a high-risk group of women, ...
... Grants API Marketing, Sales & Advertising Company Exclusive Rights to, ... ... and Canada, CEDAR KNOLLS, N.J., June 23 MedeFile,International, ... medical records management solutions, today announced,that it has granted South ...
... N.J., June 23 Medco Health,Solutions, Inc. (NYSE: ... services for,Coventry Health Care, Inc. (NYSE: CVH ... Bethesda, Md., Medco, the leading independent pharmacy ... services for all of Coventry,s Medicare,programs, covering approximately ...
... Battery-agnostic smart module combines integrated monitoring, prognostics & ... wireless ... For the third consecutive,year, Solidica, Inc. is awarded Sensors ... and leadership. This year,s,Silver honor recognized Solidica,s flagship battery ...
... SEATTLE Women,s reports of persistent, recent-onset symptoms linked ... eating or feeling full quickly and abdominal bloating ... the early detection of ovarian cancer by 20 percent, ... Cancer Research Center published online today in CANCER ...
... proper sports gear and preparation can prevent unnecessary accidents, ... A few simple safety precautions can greatly reduce the ... injuries while doing summer sports and recreational activities, says ... There were about 319,000 sports-related head injuries treated in ...
Cached Medicine News:Health News:Symptoms Plus Blood Test Boost Ovarian Cancer Detection 2Health News:Symptoms Plus Blood Test Boost Ovarian Cancer Detection 3Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 2Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 3Health News:MedeFile To Be Marketed in Over 100,000 Retail Outlets 4Health News:Coventry Health Care Awards Medicare Pharmacy Services Contract to Medco 2Health News:Coventry Health Care Awards Medicare Pharmacy Services Contract to Medco 3Health News:Solidica Awarded 2008 Best of Sensors Expo Honor for Breakthrough Battery Health Monitor 2Health News:Solidica Awarded 2008 Best of Sensors Expo Honor for Breakthrough Battery Health Monitor 3Health News:Symptom screening plus a simple blood test improves early detection of ovarian cancer 2Health News:Head Injuries All Too Common in Summer Play 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Facilitates retrieval of polypropylene guide thread from the nasal cavity when using Ritleng Bicanalicular systems and self threading Monoka systems....
... unique system uses prolene as thread-guide reducing ... The hollow Ritleng Probe is inserted into ... thread-guide is fed through it. The probe ... to pull the silicone tubing in place. ...
Medicine Products: